Table 3.

Susceptibility to faldaprevir and IFN-α of plasma sample-derived NS3 protease with treatment-emergent variants in chimeric replicons

Genotype	Placebo or NS3 varianta	No. of samples	Faldaprevir EC50 fold change relative to baseline		IFN-α EC50 fold change relative to baseline
			Mean	Range	Mean	Range
GT1a	Placebo	4	1.8	0.8–3.8	1.1	0.8–1.7
	R155K	27	330	130–520	1.3	0.5–3.1
	D168Vb	1	1800		1.3
GT1b	Placebo	4	1.2	1.0–1.3	1.0	0.6–1.9
	R155K	1	130		1.3
	D168V	11	1700	1,100–2,800	1.6	0.7–3.6
	D168E	2	180	140–210	1.3	0.5–2.1
	D168T	1	690		3.9

^aNS3 proteases from on-treatment or post-faldaprevir treatment samples. Changes in susceptibility for the placebo group were determined at day 14 relative to the baseline.

^bGT1a D168V emerged in a TN patient who had an R155 codon nucleotide sequence, CGG, similar to subtype 1b.